Cambrex Corporation. (NYSE:CBM) belongs to Healthcare sector. Its net profit margin is 16.70% and weekly performance is 3.10%. On last trading day company shares ended up $45.61. Cambrex Corporation. (NYSE:CBM) distance from 50-day simple moving average (SMA50) is 9.65%. Cambrex Corp. (NYSE:CBM) was downgraded by Zacks from a “strong-buy” rating to a “hold” rating in a note.
Viggle Inc. (NASDAQ:VGGL) shares increased 11.52% in last trading session and ended the day at $1.84. VGGL Gross Margin is 67.90% and its return on assets is -128.30%. Viggle Inc. (NASDAQ:VGGL) quarterly performance is 29.58%. On 1 July, Viggle Inc. (NASDAQ:VGGL) has announced it has priced an underwritten sale of its common stock worth $4.2 million — or 2,048,780 shares. Interestingly enough, that sale went to a single investor, the company said.
On 10 July, WPP plc (NASDAQ:WPPGY) shares increased 4.22% and was closed at $115.55. WPPGY EPS growth in last 5 year was 17.90%. WPP plc (NASDAQ:WPPGY) year to date (YTD) performance is 12.90%. WPP plc (NASDAQ:WPPGY) has reportedly teamed up with private-equity firm General Atlantic to bid for Dunnhumby, the business that developed Tesco Plc’s Clubcard loyalty program, according to people familiar with the matter.
Amdocs Limited (NASDAQ:DOX) ended the last trading day at $56.04. Company weekly volatility is calculated as 1.66% and price to cash ratio as 6.70. Amdocs Limited (NASDAQ:DOX) showed a weekly performance of 1.16%. On 8 July, Amdocs Limited (NASDAQ:DOX) declared it has accomplished the divestiture of its BSS business unit to Amdocs (DOX) for a purchase price of about $273 million. Comverse will now be singularly focused on growing its global market leadership in digital services.
On 10 July, Pfizer Inc. (NYSE:PFE) shares advanced 1.48% and was closed at $34.36. PFE EPS growth in last 5 year was 3.10%. Pfizer Inc. (NYSE:PFE) year to date (YTD) performance is 12.20%. Pfizer Inc. (NYSE:PFE) declared enrollment of the first patient in a Phase 2b clinical trial of its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (PF-06290510) in adults undergoing elective spinal fusion surgery.